menu
    • menu
    [{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"PAKISTAN","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Tralement","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Tralement","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"Heart Health Research Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Xuezhikang","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Heart Health Research Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Heart Health Research Center \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Heart Health Research Center \/ AstraZeneca"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            American Regent

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            American Regent

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tralement

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-te...

                            Details : Tralement is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Manganese Poisoning.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 10, 2023

                            Lead Product(s) : Tralement

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            American Regent

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            American Regent

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tralement

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety

                            Details : Tralement is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Manganese Poisoning.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 22, 2022

                            Lead Product(s) : Tralement

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Heart Health Research Center

                            Country arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Heart Health Research Center

                            Country arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xuezhikang

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabe...

                            Details : Xuezhikang is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lipid Metabolism Disorders.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            February 14, 2022

                            Lead Product(s) : Xuezhikang

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Getz Pharma

                            Pakistan arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus

                            Details : Insulin is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            December 17, 2021

                            Lead Product(s) : Insulin

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth